Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
Metrics: PDF 503 views | HTML 1112 views | ?
Andrea Visentin1,2, Silvia Imbergamo1, Federica Frezzato1,2, Marco Pizzi3, Roberta Bertorelle4, Edoardo Scomazzon1, Tamara Berno1, Marcello Riva1, Elisa Piva5, Monica Facco1,2, Francesco Piazza1,2, Gianpietro Semenzato1,2 and Livio Trentin1,2
1Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy
2Venetian Institute of Molecular Medicine, Centro di Eccellenza per la Ricerca Biomedica Avanzata, Padua, Italy
3General Pathology and Cytopathology Unit, Department of Medicine, University of Padua, Padua, Italy
4Immunology and Molecular Diagnostic Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy
5Unity of Laboratory Medicine, University of Padua, Padua, Italy
Livio Trentin, email: firstname.lastname@example.org
Keywords: HCL, HCL variant, bendamustine, BR, treatment naive
Received: April 21, 2017 Accepted: September 15, 2017 Published: September 28, 2017
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is characterized by unfavorable prognosis, low complete remission rates and limited disease control following classical hairy cell leukemia-based regimens. In this study, we report 3 cases of elderly patients with treatment-naive, TP53 un-mutated HCLv, who were effectively treated with four cycles of bendamustine plus rituximab. The regimen was completed in all the patients with acceptable toxicity. All patients achieved a complete clinical response with no evidence of residual disease at bone marrow biopsy and flow-cytometry examination. After a median follow-up of 19 months, the 3 subjects are still in complete remission. In this work, bendamustine plus rituximab proved to be an effective and feasible first-line treatment strategy for elderly patients with TP53 un-mutated HCLv.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.